Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Nasopharyngeal Carcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Oligoprogressive 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

pembrolizumab 16 Bevacizumab 12 Carboplatin 10 Nivolumab 8 Pemetrexed 7 Temozolomide 6 Standard of Care 6 Exercise 6 Cetuximab 6 durvalumab 5 atezolizumab 5 Prednisone 5 Cyclophosphamide 5 abemaciclib 4 Paclitaxel 4 Doxorubicin 4 Dexamethasone 4 Cisplatin 4 Blood Specimen Collection 4 temsirolimus 3 enzalutamide 3 dostarlimab 3 daratumumab 3 cabozantinib 3 Rituximab 3 Oxaliplatin 3 Metformin 3 Leucovorin 3 Lenalidomide 3 Ipilimumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Immune Checkpoint Inhibitors × 30 days × Clear all

NCT07593053 2026-05-22

PIPO

Vall d'Hebron Institute of Oncology

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡